**UoA 1 – Clinical Medicine**

REF2014 Research Activity Profile with national weighted average in brackets:



REFPE output scores compared to actual REF2014 output scores obtained:



For the **outputs** scored at 4\* subprofile, UoA 1 ranks 15th in the UK.

For the **impact** scored at 4\* subprofile, UoA 1 ranks joint 23rd in the UK with Southampton.

For the **environment** scored at 4\* subprofile, UoA 1 ranks joint 9th with ICR.

In terms of **research power**, the UoM was 12th in the UK with 0.30. UCL was first with 1.0, followed by Imperial with 0.77, Oxford with 0.57, Edinburgh with 0.47 and Cambridge with 0.45:

|  |  |  |
| --- | --- | --- |
| **HEI** | **Power** | **Prop Staff Sub** |
| University College London | 1 | 96.30406852 |
| Imperial College London | 0.773238 | 87.48167539 |
| University of Oxford | 0.571761 | 74.07142857 |
| University of Edinburgh | 0.474489 | 84.80737705 |
| University of Cambridge | 0.457717 | 76.82 |
| University of Glasgow | 0.39445 | 77.80701754 |
| University of Birmingham | 0.346739 | 70.45064378 |
| Queen Mary University of London | 0.32844 | 70.99014778 |
| Newcastle University | 0.327145 | 84.07428571 |
| King's College London | 0.322289 | 76.64044944 |
| University of Liverpool | 0.308105 | 68.00947867 |
| University of Manchester | 0.301851 | 66.10679612 |
| University of Southampton | 0.292924 | 85.35119048 |

UoM UoA 1 overall GPA was 3.19, with the sector average also being 3.19, and ranks 12th. On intensity-weighted GPA, UoM overall GPA was 2.11, with the sector average being 2.37, and ranks 20th. The percentage of eligible staff submitted was 66% with the national profile average being 74%.

Details of submission:

UoA 1 was the largest return of the University, with 149 staff submitted (followed by 147 staff returned by FLS [UoA5] and 131 by MBS [UoA 19]).

Number of eligible staff returned and FTE value: 149 at 136.18 FTE

Number of early career researchers (ECRs) returned: 10

Number of eligible staff excluded: 89

Submission rate: 66%

Number of outputs returned: 564

Standard Grade Point Average (where an output of 4\* scores 4 units, an output of 3\* scores 3 units etc.): 3.314

Weighted Grade Point Average (where an output of 4\* scores 3 units and an output of 3\* scores 1 unit; 2\* outputs and below score no units): 1.647

Number of impact case studies returned: 15

Impact case studies were selected as those in which the impact has led to tangible and far-reaching innovations affecting clinical diagnosis and therapy, and have developed the evidence base of the specialties concerned, with the ultimate goal of delivering improvements in patient care. Authors and case studies submitted were:

Peter **Clayton**: *Defining the phenotype of severe growth disorders, discovering new genes that control human growth and enhancing clinical practice*; Shaheen **Hamdy**: *Design and implementation of a new treatment for dysphagia after stroke*; Henry **Kitchener**: *Developing the evidence base for a changing cervical screening programme in England*; Ashley **Woodcock**: *Development and application of inhaled therapies in airway diseases*; David **Denning**: *Diagnostics and novel life-saving therapies for aspergillosis*; Fiona **Blackhall**: *Establishing the evidence for treatment to improve outcomes in patients with lung cancer*; Chris **Griffiths**/Rachel **Watson**: *Fibrillin-rich microfibrils and efficacy of anti-ageing cosmetics* (a redacted version will be seen by Panel members, due to the need for confidentiality);Brian **Bigger**: *Improved clinical management of lysosomal disorders*; Tony **Heagerty**/Paul **Durrington**: *Improved management of population cardiovascular risk in diabetic patients*; Vaskar **Saha**: *Improving outcomes for children with leukaemia internationally: the results of scientifically designed clinical trials and translational research*; Tony **Howell**: *Improving outcomes of women diagnosed with and at increased risk of breast cancer: the results of translational research and national and international clinical trials*; Deborah **Symmons**/Kimme **Hyrich**: *Improving treatment outcomes for patients with rheumatoid arthritis*; Nigel **Bundred**: *Preventing bone loss in patients treated for breast cancer*; Yanick **Crow**: *The global impact of gene identification at the University of Manchester*; Gareth **Evans**: *The University of Manchester’s role in establishing nationally funded forefront services for neurofibromatoses*.